Where is Macrogen located?

Macrogen is headquartered in Seoul, South Korea.

How many employees does Macrogen have?

As of Jul 31, 2026, the latest employee count at Macrogen is 211.

Is Macrogen a funded company?

Macrogen is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Macrogen rank among its competitors?

Macrogen ranks 10th amongst 611 active competitors, of which 60 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was ONCOHOST, which secured $2.8M in May, 2025.

Who are the top competitors of Macrogen?

Macrogen's top competitors include Strand Life Sciences, BGI and ONCOHOST. Among them, ONCOHOST secured the most recent funding round in May, 2025.

Macrogen - 2026 Company Profile, Team, Funding & Competitors

Macrogen is a public company based in Seoul (South Korea), founded in 1997 by Jeong Sun Seo. It operates as a Provider of a platform for next-generation sequencing. The company has 611 active competitors, including 60 funded and 65 that have exited. Its top competitors include companies like Strand Life Sciences, BGI and ONCOHOST.

Company Details

Macrogen provides a platform for next-generation sequencing. The company provides diversified genomics services such as next-generation sequencing and analysis of the data obtained, capillary sequencing, microarray analysis (using the chip from Illumina, Affymetrix, and Agilent), oligonucleotide synthesis, and data analytics services. It also offers custom transgenic mice and knockout mouse models.

Website: macrogen.com
Social
Email ID: *****@macrogen.com

Key Metrics

Founded Year

1997

Location

Seoul, South Korea

Stage

Public

Investors

Atinum Investment & 2 more

Ranked

10^th among 611 active competitors

Employee Count

211 as on Jul 31, 2026

Investment & Acquisitions

Microba

Similar Companies

Strand Life Sciences & 846 more

Exit Details

Public

View Macrogen's full profile

Macrogen got listed on Feb 22, 2000.

Click here to take a look at Macrogen's IPO in detail

Macrogen is a funded company. Macrogen has 3 institutional investors.

View details of Macrogen's funding rounds and investors

The founders of Macrogen is Jeong Sun Seo. Hyonyong Chong is the CEO of Macrogen.

Here are the details of Macrogen's key team members:

Jeong Sun Seo: Founder of Macrogen.
Hyonyong Chong: Co-CEO of Macrogen.

View details of Macrogen's Founder profiles and Board Members

Macrogen's employee count trend

Macrogen has 211 employees as of Jul 26. Here is Macrogen's employee count trend over the years:

Uncover Macrogen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Macrogen include Strand Life Sciences, BGI and ONCOHOST. Here is the list of Top 10 competitors of Macrogen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Strand Life Sciences 2000, Bengaluru (India), Acquired	Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery	$34.9M	Biomark Capital, Quadria Capital & 92 others	73/100
2nd	BGI 1999, Shenzhen (China), Public	Provider of services in genome sequencing	-	Sequoia Capital China, Yunfeng Capital & 15 others	64/100
3rd	ONCOHOST 2017, Binyamina Giv at Ada (Israel), Series C	AI-based oncology therapy plan solution for professionals	$43M	ALIVE, OurCrowd & 5 others	60/100
4th	Enara Bio 2016, Oxford (United Kingdom), Series B	Developer of T-cell based cancer-cell interface for therapeutics	$84.1M	M Ventures, SV Health Investors & 36 others	53/100
5th	Genewiz 1999, South Plainfield (United States), Acquired	Provider of a wide range of genomic services for the life sciences industry	-	Orbimed, Ampersand Capital & 6 others	53/100
6th	Berry Genomics 2010, Beijing (China), Public	Provider of genetic testing products and tests	$16M	Legend Capital, TMCP & 6 others	50/100
7th	Dante Omics 2016, New York City (United States), Unfunded	Provider of genomic services and solutions for researchers, laboratories, and healthcare professionals	-	-	48/100
8th	Amplia Therapeutics 2000, North Melbourne (Australia), Public	Developer of therapies for treating cancer and pulmonary fibrosis	-	-	47/100
9th	Transnetyx 2000, Memphis (United States), Acquired	Developer of automated-genotyping services for murine cell lines	-	Abacus Finance Group, ventureCapital.org & 2 others	47/100
10th	Macrogen 1997, Seoul (South Korea), Public	Provider of a platform for next-generation sequencing	-	Atinum Investment, Aju IB Investment & 1 others	47/100